BioMedNet has just moved into the institutional market with a new product which it claims awill empower researchers to create their own review journals’.
BioMedNet has just moved into the institutional market with a new product which it claims awill empower researchers to create their own review journals’.
BioMedNet Reviews (http://reviews.bmn.com), contained on the BioMedNet site, contains the world’s highest cited collection of life science review articles that enables researchers to personalise the content to match theirparticular research needs. It contains more than 100 key life science titles from Elsevier Science and includes the Trends and Current Opinion titles, such as Trends in Pharmacological Sciences and Current Opinion in Biotechnology. In addition, review material from original research titles, including FEBS letters and Brain Research, form an important part. BioMedNet Reviews is an expanding resource with 200 new review articles being added each month to the 10000 articles it already features including some archive material back to 1994.
Personalisation is central to the thinking behind BioMedNet Reviews, and a key feature of the service is a four step process that enables users to create their own avirtual journals’. Selecting articles using a mix of subject classifications and specific key words ensures the final selection of material is exactly tailored to a user’s research needs. Each virtual journal takes only seconds to create, and once set up, appropriate review articles are automatically added as soon as they are published whilst an email alerting service makes sure nothing will pass the user by. While BioMedNet Reviews contains full text review articles only researchers can explore an area in greater depth by linking to the original full text article via BioMedNet’s MEDLINE enabling extensive abstract and index searching across 3500 journals to be performed with ease.
BioMedNet Reviews is sold by subscription to institutes with prices determined by user population size and access via a defined IP domain. BioMedNet is now running further 90 day no-obligation trials for institutes.
ENQUIRY No 8
BioMedNet is based in London, UK. www.bmn.com
